A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease
Fibrostenosis is a serious complication of Crohn’s disease (CD), affecting approximately one-half of all patients. Surgical resection is the typical clinical end due to ineffective antifibrotic therapy mainly through anti-inflammatory treatment and fibrosis can be reverted only at early stages. Move...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/78d1d0c6b99245518d945c1a3368d2a5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:78d1d0c6b99245518d945c1a3368d2a5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:78d1d0c6b99245518d945c1a3368d2a52021-11-11T05:59:04ZA Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease2296-889X10.3389/fmolb.2021.762355https://doaj.org/article/78d1d0c6b99245518d945c1a3368d2a52021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmolb.2021.762355/fullhttps://doaj.org/toc/2296-889XFibrostenosis is a serious complication of Crohn’s disease (CD), affecting approximately one-half of all patients. Surgical resection is the typical clinical end due to ineffective antifibrotic therapy mainly through anti-inflammatory treatment and fibrosis can be reverted only at early stages. Mover, human fibrotic disorders is known to be associated with aging process. Thus, accurate monitoring of the progression of fibrosis is crucial for CD management as well as can be benefit to aging related fibrosis. The excessive deposition of type I collagen (ColI) is the core point in major complications of fibrosis, including that in patients with CD and aging related fibrosis. Therefore, a MR imaging probe (EP-3533) targeted ColI was employed to stage bowel fibrosis in CD using a rat model and to compare its efficiency with the common MR imaging contrast medium gadopentetatedimeglumine (Gd-DTPA). The bowel fibrotic rat model was established with different degrees of bowel fibrosis, were scanned using a 3.0-T MRI scanner with a specialized animal coil. MRI sequence including T1 mapping and T1-weighed imaging were performed before and after injecting the MRI probe (EP-3533 or Gd-DTPA). The T1 relaxation time (T1 value) and change in the contrast-to-noise ratio (ΔCNR) were measured to evaluate bowel fibrosis. Masson’s trichrome staining was performed to determine the severity of fibrosis. EP-3533 offered a better longitudinal relaxivity (r1) with 67.537 L/mmol·s, which was approximately 13 times that of Gd-DTPA. The T1 value on bowel segments was reduced in the images from EP-3533 compared to that from Gd-DTPA (F = 16.478; p < 0.001). Additionally, a better correlation between ΔCNR calculated from EP-3533 imaging and bowel fibrosis (AUC = 0.846) was determined 10 min after enhanced media administration than with Gd-DTPA (AUC = 0.532). The 10th-minute ΔCNR performed using the ColI probe showed the best correlation with the severity of bowel fibrosis (r = 0.538; p = 0.021). Our results demonstrates that targeted MRI probe (EP-3533) supplies a better enhanced effect compared to Gd-DTPA and could be a promising method to evaluate the progression and monitor the therapeutic response of bowel fibrosis.Zhoulei LiBaolan LuJinjiang LinShaofu HeLi HuangYangdi WangJixin MengZiping LiShi-Ting FengShaochun LinRen MaoXue-Hua LiFrontiers Media S.A.articlefibrosisColI-targeted theranostic probeCrohn’s diseasemolecular imagingtype I collagenBiology (General)QH301-705.5ENFrontiers in Molecular Biosciences, Vol 8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
fibrosis ColI-targeted theranostic probe Crohn’s disease molecular imaging type I collagen Biology (General) QH301-705.5 |
| spellingShingle |
fibrosis ColI-targeted theranostic probe Crohn’s disease molecular imaging type I collagen Biology (General) QH301-705.5 Zhoulei Li Baolan Lu Jinjiang Lin Shaofu He Li Huang Yangdi Wang Jixin Meng Ziping Li Shi-Ting Feng Shaochun Lin Ren Mao Xue-Hua Li A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease |
| description |
Fibrostenosis is a serious complication of Crohn’s disease (CD), affecting approximately one-half of all patients. Surgical resection is the typical clinical end due to ineffective antifibrotic therapy mainly through anti-inflammatory treatment and fibrosis can be reverted only at early stages. Mover, human fibrotic disorders is known to be associated with aging process. Thus, accurate monitoring of the progression of fibrosis is crucial for CD management as well as can be benefit to aging related fibrosis. The excessive deposition of type I collagen (ColI) is the core point in major complications of fibrosis, including that in patients with CD and aging related fibrosis. Therefore, a MR imaging probe (EP-3533) targeted ColI was employed to stage bowel fibrosis in CD using a rat model and to compare its efficiency with the common MR imaging contrast medium gadopentetatedimeglumine (Gd-DTPA). The bowel fibrotic rat model was established with different degrees of bowel fibrosis, were scanned using a 3.0-T MRI scanner with a specialized animal coil. MRI sequence including T1 mapping and T1-weighed imaging were performed before and after injecting the MRI probe (EP-3533 or Gd-DTPA). The T1 relaxation time (T1 value) and change in the contrast-to-noise ratio (ΔCNR) were measured to evaluate bowel fibrosis. Masson’s trichrome staining was performed to determine the severity of fibrosis. EP-3533 offered a better longitudinal relaxivity (r1) with 67.537 L/mmol·s, which was approximately 13 times that of Gd-DTPA. The T1 value on bowel segments was reduced in the images from EP-3533 compared to that from Gd-DTPA (F = 16.478; p < 0.001). Additionally, a better correlation between ΔCNR calculated from EP-3533 imaging and bowel fibrosis (AUC = 0.846) was determined 10 min after enhanced media administration than with Gd-DTPA (AUC = 0.532). The 10th-minute ΔCNR performed using the ColI probe showed the best correlation with the severity of bowel fibrosis (r = 0.538; p = 0.021). Our results demonstrates that targeted MRI probe (EP-3533) supplies a better enhanced effect compared to Gd-DTPA and could be a promising method to evaluate the progression and monitor the therapeutic response of bowel fibrosis. |
| format |
article |
| author |
Zhoulei Li Baolan Lu Jinjiang Lin Shaofu He Li Huang Yangdi Wang Jixin Meng Ziping Li Shi-Ting Feng Shaochun Lin Ren Mao Xue-Hua Li |
| author_facet |
Zhoulei Li Baolan Lu Jinjiang Lin Shaofu He Li Huang Yangdi Wang Jixin Meng Ziping Li Shi-Ting Feng Shaochun Lin Ren Mao Xue-Hua Li |
| author_sort |
Zhoulei Li |
| title |
A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease |
| title_short |
A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease |
| title_full |
A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease |
| title_fullStr |
A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease |
| title_full_unstemmed |
A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn’s Disease |
| title_sort |
type i collagen-targeted mr imaging probe for staging fibrosis in crohn’s disease |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/78d1d0c6b99245518d945c1a3368d2a5 |
| work_keys_str_mv |
AT zhouleili atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT baolanlu atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT jinjianglin atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT shaofuhe atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT lihuang atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT yangdiwang atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT jixinmeng atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT zipingli atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT shitingfeng atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT shaochunlin atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT renmao atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT xuehuali atypeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT zhouleili typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT baolanlu typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT jinjianglin typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT shaofuhe typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT lihuang typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT yangdiwang typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT jixinmeng typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT zipingli typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT shitingfeng typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT shaochunlin typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT renmao typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease AT xuehuali typeicollagentargetedmrimagingprobeforstagingfibrosisincrohnsdisease |
| _version_ |
1718439503888121856 |